We are live on ! Find out more
EDIT icon

Editas Medicine

239 hedge funds and large institutions have $1.55B invested in Editas Medicine in 2020 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 84 increasing their positions, 58 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $33.3M | Put options by funds: $14.3M

45% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 58

2% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 43

0% more funds holding

Funds holding: 238239 (+1)

0.24% less ownership

Funds ownership: 88.82%88.57% (-0.24%)

4% less capital invested

Capital invested by funds: $1.61B → $1.55B (-$61M)

Holders
239
Holders Change
+1
Holders Change %
+0.42%
% of All Funds
4.82%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
44
Increased
84
Reduced
58
Closed
43
Calls
$33.3M
Puts
$14.3M
Net Calls
+$19M
Net Calls Change
-$15.2M
Name Holding Trade Value Shares
Change
Change in
Stake
MSL
51
Mackay Shields LLC
New York
$1.73M -$391K -12,000 -16%
LPL Financial
52
LPL Financial
California
$1.61M +$158K +4,844 +9%
UBS AM
53
UBS AM
Illinois
$1.6M +$304K +9,323 +20%
PPA
54
Parametric Portfolio Associates
Washington
$1.58M +$177K +5,436 +11%
Mirae Asset Global Investments
55
Mirae Asset Global Investments
South Korea
$1.42M +$519K +15,921 +46%
RJFSA
56
Raymond James Financial Services Advisors
Florida
$1.35M +$48.8K +1,498 +3%
ECM
57
ExodusPoint Capital Management
New York
$1.32M +$702K +21,563 +85%
Barclays
58
Barclays
United Kingdom
$1.32M -$129K -3,973 -8%
Legal & General Group
59
Legal & General Group
United Kingdom
$1.3M +$37.1K +1,140 +3%
Los Angeles Capital Management
60
Los Angeles Capital Management
California
$1.28M -$452K -13,890 -23%
WG
61
Winton Group
United Kingdom
$1.27M +$1.11M +33,962 +297%
Fidelity Investments
62
Fidelity Investments
Massachusetts
$1.22M -$2.72M -83,421 -66%
EWM
63
Elmwood Wealth Management
California
$1.18M
Jane Street
64
Jane Street
New York
$1.12M -$1.61M -49,307 -55%
MFAM
65
Motley Fool Asset Management
Virginia
$1.11M +$85K +2,610 +7%
Deutsche Bank
66
Deutsche Bank
Germany
$1.09M -$31.8K -977 -2%
Thrivent Financial for Lutherans
67
Thrivent Financial for Lutherans
Minnesota
$1.08M +$1.25M +38,530 New
TW
68
TrinityPoint Wealth
Connecticut
$1.07M +$1.24M +38,047 New
AIG
69
American International Group
New York
$1.05M +$118K +3,632 +11%
Manulife (Manufacturers Life Insurance)
70
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$997K +$79.7K +2,447 +7%
SCM
71
Shelton Capital Management
Colorado
$982K
KOCAA
72
Knights of Columbus Asset Advisors
Connecticut
$974K -$166K -5,108 -13%
Bank of America
73
Bank of America
North Carolina
$952K -$2.72M -83,573 -71%
Capital Fund Management (CFM)
74
Capital Fund Management (CFM)
France
$903K +$1.05M +32,166 New
CSS
75
Cubist Systematic Strategies
Connecticut
$877K +$201K +6,158 +25%

EDIT Hedge Fund Activity: Q3 2020 in Review

239 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2020, worth a combined $1.55B — down 3.8% from $1.61B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new EDIT positions and 43 closed out — a net gain of 1 holder — while 84 added to existing stakes and 58 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $102M. The largest seller was CAAS Capital Management, exiting entirely with an estimated $41.3M sold.

  • 239 institutional investors held Editas Medicine (EDIT) as of Q3 2020, up from 238 in Q2 2020.
  • Funds reported $1.55B of Editas Medicine stock for Q3 2020, down 3.8% quarter-over-quarter.
  • 44 funds opened new Editas Medicine positions in Q3 2020 and 43 closed out, a net change of +1 holder.
  • The largest Editas Medicine buyer in Q3 2020 was ARK Investment Management, an estimated $102M added.
  • The largest Editas Medicine seller in Q3 2020 was CAAS Capital Management, an estimated $41.3M sold.

Based on aggregated 13F filings for Q3 2020.